CD63 and cancer: Interestingly, of the positive cases, TNBC cancers represented the highest proportion of the cases with strong CD63 staining intensity (Figure 1H(ii)), with 58% of the positive cases demonstrating strong CD63 immunohistochemistry (IHC) expression compared to only 7% of ER+HER2− cases.